Search Results - cancers

336 Results

Sort By:

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumorsJHU Ref #: C15411 Unmet NeedCancer is the second leading cause of death in the United States, with an estimated 1.8 million cases having been diagnosed and 606,520 people having succumbed to the disease in 2020. The most common cancer diagnosis...

Published: 3/13/2026 | Inventor(s): Stavroula Sofou, Alaina Howe

Keywords(s): Breast Cancer, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology

L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection

C10218: L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection Value Proposition: • A broadly protective vaccine against HPV. • Can be delivered without needles. • Can be chemically synthesized at low cost. Technical Details: Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the...

Published: 3/12/2026 | Inventor(s): Hannah Alphs-Jackson, Ratish Gambhira, Richard Roden

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 3/12/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

PSMA-targeted Nanoparticles for Therapy of Prostate Cancer

PSMA-targeting nanoparticle for prostate cancer therapyJHU Ref #: C10180Value Proposition:· Engineered nanoparticle system with potent urea-based PSMA inhibitor· Drug loaded nanoparticle· Specific and selective tumor cytotoxicity Unmet NeedProstate cancer affects millions of men globally and is a leading cause of cancer death in...

Published: 3/12/2026 | Inventor(s): Martin Pomper, Ronnie Mease, Sachin Chandran, Sangeeta Ray, Samuel Denmeade

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

A Novel-fate Marking Strategy to Permanently Tag Hypoxic Cancer Cells

Value Proposition· Permanently labels cells that have experienced hypoxia, enabling long-term tracking· Captures tumor evolution by identifying cells with past hypoxia exposure, not just at the time of tissue collection· Enables investigation of metastasis by tracking cells from hypoxic niches that may retain aggressive phenotypes· Supports...

Published: 3/13/2026 | Inventor(s): Daniele Gilkes, Ines Godet

Keywords(s): Breast Cancer, Cancers, Cardiovascular Diseases, Cell Lines, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, In Vivo Research Tool, Mouse Model, Translational Research Biomarker

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines

Targeted chemo-immunotherapy delivery

Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...

Published: 3/12/2026 | Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

Mimetic peptides derived from collagen type IV for the treatment of angiogenesis-dependent diseases

C11348: Novel Anti-Angiogenic Collagen Derived Mimetic PeptidesNovelty:modified peptides from collagen IV derived parent peptide Pentastatin-1Value Proposition:The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:• Ability...

Published: 3/12/2026 | Inventor(s): Niranjan Pandey, Elena Rosca, Corban Rivera, Jacob Koskimaki, Amir Tamiz, Aleksander Popel

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Protein, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

Anti-Fungal Drug Analogs to Treat Cancer by Preventing Angiogenesis and Hedgehog Pathway Activity

Value Proposition· Itraconazole is in clinical trials for cancer treatment as it is known to have antiangiogenic activity and anti-Hedgehog pathway activity, but its use has been limited by its potent inhibition of the drug metabolizing enzyme CYP3A4· The designed analog for itraconazole has greater antiangiogenic potency without CYP3A4 inhibition...

Published: 3/12/2026 | Inventor(s): Jun Liu, Wei Shi, Kalyan Kumar Pasunooti, Wukun Liu, Ruojing Li, Sarah Head, Yingjun Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Eye Disorders, Macular Degeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration

Compositions and Biomarkers for Human Cancer and Methods of Use

Novel biomarkers for the detection and prognosis of several cancersJHU REF: C12506 Invention novelty: This invention has discovered high frequency mutations in the telomerase reverse transcriptase (TERT) promoter of certain cancers. Value Proposition: Early detection is usually critical for the successful treatment of cancer, therefore there is...

Published: 3/12/2026 | Inventor(s): Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Chetan Bettegowda, Yuchen Jiao, Darell Bigner, Hai Yan, Zachary Reitman, Patrick Killela

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Novel monoclonal antibody inhibitors targeting potassium channel KCNK9

Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...

Published: 3/12/2026 | Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer

1 2 3 4 5 6 7 8 9 10 ...